Skip to main content

Funding Opportunity – American Cancer Society-Institutional Research Grant (IRG)

Submitted by vicc_migrate on
Applications are being solicited for support by the American Cancer Society‐Institutional Research Grant (IRG). These funds are designed to provide seed money to support junior faculty members with an interest in cancer research who do not have external grant support. Deadline:

VICC breast cancer leaders named Komen Scholars

Submitted by vicc_migrate on
Ingrid Mayer, MD, MSCI, Ingram Professor of Cancer Research and leader of the Breast Cancer Research Program, has been named a Komen Scholar for her leadership in breast cancer research. She is joined by Wayne Dornan, PhD, a patient research advocate at VICC, who will serve on the Advocates in Science Steering Committee for Susan G. Komen.

Natasha B. Halasa, M.D., M.P.H.

  • Professor of Pediatrics

Email

natasha.halasa@vumc.org
Division of Pediatric Infectious Diseases
D-7232 Medical Center North
1161 21st Ave South
Nashville, TN 37232

Natasha B. Halasa, M.D., M.P.H.

  • Professor of Pediatrics

natasha.halasa@vumc.org

Division of Pediatric Infectious Diseases
D-7232 Medical Center North
1161 21st Ave South
Nashville, TN 37232

Research Program

Research Description

Have any questions? Contact Us 1-877-936-8422 for more information

Michael K. Gibson, M.D., Ph.D.

  • Associate Professor of Medicine
  • Director of Translational Research for Head and Neck Oncology

Phone

(615) 322-4967

Email

mike.gibson.1@vumc.org
Division of Hematology and Oncology
2220 Pierce Avenue
777 Preston Research Building
Nashville, TN 37232

Michael K. Gibson, M.D., Ph.D.

  • Associate Professor of Medicine
  • Director of Translational Research for Head and Neck Oncology

(615) 322-4967

mike.gibson.1@vumc.org

Division of Hematology and Oncology
2220 Pierce Avenue
777 Preston Research Building
Nashville, TN 37232

Research Program

Research Description

Have any questions? Contact Us 1-877-936-8422 for more information

Daniel Fabbri, Ph.D.

  • Associate Professor of Biomedical Informatics
  • Associate Professor of Computer Science

Phone

(615) 343-0089

Email

daniel.fabbri@vumc.org
Department of Biomedical Informatics
2525 West End Ave, Suite 800
Nashville, TN 37203

Daniel Fabbri, Ph.D.

  • Associate Professor of Biomedical Informatics
  • Associate Professor of Computer Science

(615) 343-0089

daniel.fabbri@vumc.org

Department of Biomedical Informatics
2525 West End Ave, Suite 800
Nashville, TN 37203

Research Program

Research Description

Have any questions? Contact Us 1-877-936-8422 for more information

Sebastian Joyce, Ph.D.

  • Dorothy B. and Theodore R. Austin Professor of Pathology
  • Professor of Pathology, Microbiology and Immunology

Phone

(615) 322-1472

Email

sebastian.joyce@vumc.org
Dept of Pathology, Microbiology and Immunology
A-4223 Medical Center North
1161 21st Ave
Nashville, TN 37232-2363

Sebastian Joyce, Ph.D.

  • Dorothy B. and Theodore R. Austin Professor of Pathology
  • Professor of Pathology, Microbiology and Immunology

(615) 322-1472

sebastian.joyce@vumc.org

Dept of Pathology, Microbiology and Immunology
A-4223 Medical Center North
1161 21st Ave
Nashville, TN 37232-2363

Research Program

Research Description

Have any questions? Contact Us 1-877-936-8422 for more information

Stacie B. Dusetzina, Ph.D.

  • Ingram Professor of Cancer Research
  • Co-Leader, Cancer Health Outcomes and Control Research Program
  • Professor of Health Policy

Phone

(615) 875-9281

Email

s.dusetzina@vumc.org
Department of Health Policy
2525 West End Ave, Suite 1200
Nashville, TN 37203

Stacie B. Dusetzina, Ph.D.

  • Ingram Professor of Cancer Research
  • Co-Leader, Cancer Health Outcomes and Control Research Program
  • Professor of Health Policy

(615) 875-9281

s.dusetzina@vumc.org

Department of Health Policy
2525 West End Ave, Suite 1200
Nashville, TN 37203

Research Program

Research Description

Have any questions? Contact Us 1-877-936-8422 for more information
This phase III trial studies how well active surveillance help doctors to monitor subjects with low risk germ cell tumors for recurrence after their tumor is removed. When the germ cell tumors has spread outside of the organ in which it developed, it is considered metastatic. Drugs used in chemotherapy, such as bleomycin, carboplatin, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. The trial studies whether carboplatin or cisplatin is the preferred chemotherapy to use in treating metastatic standard risk germ cell tumors.
Subscribe to